A viral vector vaccine uses a harmless or weakened virus as a delivery vehicle to carry genetic instructions for a target pathogen’s protein into your cells, where your immune system learns to recognize and fight it. The vector virus itself does not cause the disease you are vaccinating against, nor does it typically cause the disease it was originally derived from. This approach proved its worth most visibly during the COVID-19 pandemic with the Oxford-AstraZeneca and Johnson & Johnson vaccines, but the technology has roots stretching back decades into veterinary medicine and gene therapy research, and is now branching into areas like cancer treatment.
How a Viral Vector Delivers Its Cargo
The basic idea is straightforward: scientists take a virus that is good at getting inside human cells and strip out the parts that let it reproduce or cause illness. In place of those deleted genes, they insert a gene encoding a protein from the pathogen you want protection against. For COVID-19 vaccines, that inserted gene coded for the SARS-CoV-2 spike protein. When this engineered virus enters your cells, the cellular machinery reads the new gene and produces the target protein on the cell surface. Your immune system spots it, flags it as foreign, and mounts a response. The vector is essentially a Trojan horse, smuggling instructions past the cell membrane.
Different viruses are chosen as vectors based on how efficiently they enter cells, how much foreign genetic material they can carry, and how well-understood their biology is. Adenoviruses have been among the most popular choices for vaccines because they infect cells readily, provoke strong immune reactions, and can accommodate reasonably large gene inserts. Viral vectors can enhance immunogenicity without needing a separate adjuvant and can trigger robust responses from cytotoxic T cells, the immune cells responsible for hunting down and killing infected cells.1PubMed Central. Developments in Viral Vector-Based Vaccines That dual ability to stimulate both antibody production and cellular killing is one of the technology’s key selling points over some older vaccine platforms.
Replicating Versus Non-Replicating Vectors
Viral vectors fall into two broad categories. Non-replicating vectors have been engineered so they cannot copy themselves once inside your body. They enter cells, deliver the gene, and that is it. The Oxford-AstraZeneca (ChAdOx1) and Johnson & Johnson (Ad26.COV2.S) COVID-19 vaccines both used non-replicating adenovirus vectors. Because these vectors cannot multiply, the dose you receive is the dose that acts on your immune system, and there is no risk of the vector spreading to other tissues or other people.
Replicating vectors, by contrast, retain the ability to make limited copies of themselves after injection. The advantage is that a smaller initial dose can produce a larger immune stimulus as the vector amplifies. A proposed strategy involves priming first with a replicating vector to engage the innate immune system and stimulate both cellular and antibody responses across mucosal and systemic compartments, then boosting later with a non-replicating vector or protein subunit to push protective immunity to the levels needed.2PubMed Central. Replicating and non-replicating viral vectors for vaccine development The best-known replicating vector vaccine is the rVSV-ZEBOV Ebola vaccine, built on vesicular stomatitis virus, which showed high efficacy in outbreak settings using a ring vaccination approach.3PubMed. Vaccines against Ebola virus
The trade-off is safety versus potency. Non-replicating vectors have a cleaner safety profile because what you inject is all you get. Replicating vectors can generate stronger immune responses from smaller doses, which matters for logistics and cost, but regulators scrutinize them more closely because any self-copying biological agent needs to be tightly controlled.
The Pre-Existing Immunity Problem
One of the biggest practical hurdles for adenovirus-based vaccines is that many people have already been infected by common adenoviruses throughout their lives. If your immune system recognizes the vector itself from a past natural infection, it may attack and neutralize the delivery vehicle before it can do its job. This is not a theoretical concern. In primate studies, pre-existing immunity to human adenovirus serotype 5 (AdHu5) completely blocked the induction of antibodies against the delivered target protein.4PubMed Central. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors
The workaround has been to use adenoviruses that most humans have never encountered. The Oxford-AstraZeneca vaccine, for example, used a chimpanzee adenovirus (ChAdOx1), which sidesteps the problem neatly. Research on an Ebola vaccine confirmed the logic: pre-existing immunity to human adenoviruses severely compromised the human Ad5-based vaccine but did not affect the chimpanzee-derived version.5PubMed. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus Johnson & Johnson chose serotype Ad26 for similar reasons, as it is a rarer human adenovirus that fewer people carry antibodies against. The choice of vector serotype, then, is not an academic detail. It can be the difference between a vaccine that works broadly across populations and one that fails in regions where the common adenovirus has already swept through.
What Happens Inside the Immune System
When a viral vector enters your body, the immune response unfolds in layers. The first responders belong to the innate immune system, the rapid but nonspecific alarm network. Research on adenoviral vectors has shown that this initial detection happens through multiple parallel pathways. One type of immune cell recognizes adenoviral DNA through a receptor called TLR9, while other cell types detect the viral DNA through a separate, TLR-independent route that senses it inside the cell’s interior. Both pathways converge on producing type I interferons, signaling molecules that amplify the alarm and start recruiting adaptive immune cells.6PubMed Central. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways
This innate activation is not a side effect. It is a feature. It acts as a built-in adjuvant, priming the adaptive immune system to mount a stronger, more focused response against the target protein. The adaptive arm then produces antibodies (B cell response) and killer T cells (CD8+ T cell response) that are specifically trained to recognize the vaccine-encoded protein. Research into engineering even stronger T cell responses has shown that fusing certain molecular tags onto the target protein can dramatically increase the proportion of T cells that respond. In one clinical study, up to roughly 30% of CD8+ T cells targeted single viral epitopes, and these cells were predominantly effector memory cells primed for rapid action.7PubMed Central. MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans
How Viral Vector Vaccines Compare to mRNA Vaccines
The COVID-19 pandemic gave the public a side-by-side comparison of two technologies that had never been deployed at this scale. The mRNA vaccines from Pfizer-BioNTech and Moderna and the adenovirus-vector vaccines from AstraZeneca and Johnson & Johnson targeted the same spike protein but got there by different routes. Multi-omics profiling of people who received either the ChAdOx1 (AstraZeneca) or BNT162b2 (Pfizer) vaccine revealed genuinely different immune signatures in the days after vaccination. About six days after the first dose of the adenovirus vector vaccine, researchers identified over 400 differentially expressed genes, along with striking increases in plasmablasts and activated circulating T follicular helper cells. By contrast, the mRNA vaccine produced no detectable gene expression changes or immune cell shifts at the same time point.8Cell Reports Medicine. Multi-omics profiling of immune responses to mRNA and adenovirus-vectored COVID-19 vaccines
This does not mean one platform is simply “better.” The adenovirus vector triggered a more visible early immune activation, but after a second dose the mRNA vaccine generally produced higher antibody titers. Importantly, after a third dose of an mRNA vaccine, antibody levels converged regardless of whether the first doses had been the vector or mRNA vaccine.8Cell Reports Medicine. Multi-omics profiling of immune responses to mRNA and adenovirus-vectored COVID-19 vaccines One imaging study noted that vaccine-related lymph node reactions were about twice as common after the Pfizer mRNA vaccine compared to the AstraZeneca vector vaccine, and the mRNA vaccine also produced higher metabolic activity in axillary lymph nodes.9PubMed Central. Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and 18F-FDG PET/CT features These imaging differences suggest the two platforms stimulate somewhat different local tissue responses, though the clinical significance of that is still being worked out.
The practical advantages of viral vector vaccines tend to show up in logistics. Adenovirus vectors are physically sturdier than mRNA wrapped in lipid nanoparticles. Freeze-dried adenovirus-based products can be stored at standard refrigerator temperatures with shelf lives measured in years. Even liquid formulations can be kept at two to eight degrees Celsius for months.10Elsevier / Journal of Pharmaceutical Sciences. The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines The early Pfizer mRNA vaccine required ultra-cold storage at minus 70 degrees, a dealbreaker for many low- and middle-income countries. This cold-chain advantage made viral vector vaccines the backbone of early pandemic vaccination campaigns in parts of Africa and South Asia.
Safety and the Thrombosis Concern
Viral vector vaccines have a generally strong safety record, with the most common reactions being the familiar injection-site soreness, fatigue, and low-grade fever that signal immune activation. But the adenovirus-vector COVID-19 vaccines drew intense scrutiny after reports of a rare but serious clotting disorder known as vaccine-induced immune thrombotic thrombocytopenia, or VITT. This condition involved unusual blood clots combined with low platelet counts, sometimes in dangerous locations like the brain’s venous sinuses.
The mechanism appears to involve platelet factor 4 (PF4), a protein that binds to adenovirus particles and, in rare cases, triggers an antibody response resembling what happens in heparin-induced thrombocytopenia. Researchers have been investigating how PF4 interacts with both assembled adenovirus particles and non-assembled adenovirus proteins in the ChAdOx1 and Ad26.COV2.S vaccines, as well as whether other vaccine constituents play a role.11PubMed Central. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT) The condition was extremely rare, occurring in roughly one to two cases per hundred thousand doses depending on the population studied, but the severity of cases and the availability of mRNA alternatives led regulators in several countries to restrict or withdraw the adenovirus-vector COVID-19 vaccines.
A cross-national survey across six EU member states found that knowledge of VITT measurably reduced people’s willingness to receive the AstraZeneca or Johnson & Johnson vaccines. Willingness varied significantly between countries and appeared to track with how national health authorities communicated about the risk.12PubMed. Public’s perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions It is worth noting that VITT has been linked specifically to certain adenovirus-vector COVID-19 vaccines and does not appear to be an inherent problem with all viral vector vaccines. The rVSV Ebola vaccine, for instance, uses a completely different vector and has not shown the same clotting signal.
Manufacturing and Quality Control
Making viral vector vaccines at pandemic scale exposed bottlenecks that the industry had not previously faced. The vectors need to be grown inside living cells, and the workhorse cell line for adenovirus production has been HEK293 and its derivatives. Recent molecular characterization of these cell lines has enabled re-engineering for better performance, including identifying safe locations in the genome for gene insertion and developing defined, serum-free media that can support large-scale suspension cultures.13PubMed. Molecular characterization of HEK293 cells as emerging versatile cell factories Moving from laboratory-scale to commercial-scale production at viable costs remains a work in progress, particularly for gene therapy applications where viral vector doses can be much larger than vaccine doses.
Quality control for non-replicating adenovirus vectors includes mandatory testing for replication-competent adenovirus (RCA), essentially making sure that none of the viral particles in your vaccine batch have regained the ability to reproduce. This testing is required before any clinical material can be released.14PubMed. A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells It is a critical safety checkpoint, because if even a small number of replication-competent particles slipped through, the vaccine could behave unpredictably in immunocompromised recipients.
Beyond COVID and Ebola
Viral vector vaccines existed before COVID-19 and will outlast it. The Ebola story is instructive: during the 2014-2016 West African outbreak, an extraordinary global collaboration accelerated multiple candidate vaccines through clinical development, with more than 15 different vaccines in preclinical work and 8 reaching clinical evaluation. These included DNA vaccines, virus-like particles, and viral vectors based on vesicular stomatitis virus, human and chimpanzee adenoviruses, and vaccinia virus.15PubMed Central. Clinical development of Ebola vaccines The rVSV-ZEBOV vaccine that emerged from this effort was the first viral vector vaccine to demonstrate high efficacy in a phase III trial, using a ring vaccination strategy where contacts of confirmed cases were vaccinated to create a protective buffer.
Cancer immunotherapy is another active frontier. Viruses are naturally good at triggering immune responses, and they can be engineered to express tumor-associated proteins. When a viral vector carrying a tumor antigen gene infects antigen-presenting cells like dendritic cells, it can dramatically increase the number and effectiveness of killer T cells that specifically target tumor cells bearing that antigen.16PubMed Central. Viral vector-based therapeutic cancer vaccines The challenge with cancer vaccines is that tumor antigens are often similar to the body’s own proteins, so the immune system is naturally reluctant to attack them aggressively. Viral vectors help overcome that reluctance by packaging the antigen in a context that screams “foreign threat” to the immune system.
Veterinary medicine was actually one of the earliest proving grounds for viral vector vaccines. Recombinant vaccinia-based and canarypox-based vaccines have been used in animals for years, protecting against diseases like rabies in wildlife, avian influenza in poultry, and distemper in ferrets. The criteria for choosing a vector in veterinary applications mirror the human considerations: does it provide a delivery or manufacturing advantage over existing vaccines, does it improve safety, and does it extend the duration of immunity?
Next-Generation Vector Engineering
The current generation of viral vector vaccines, for all its success, has clear limitations: pre-existing immunity neutralizing the vector, the VITT signal with certain adenovirus platforms, and the challenge of re-using the same vector for booster doses because the immune system starts targeting the delivery vehicle after the first exposure. Researchers are addressing all of these through capsid engineering, essentially redesigning the outer protein shell of the virus.
Modern approaches combine rational design, directed evolution, and machine learning to produce novel capsid variants with improved ability to enter target cells, reduced immunogenicity so the vector escapes immune surveillance, and better tissue-specific targeting.17PubMed Central. Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning One concrete strategy involves modifying the glycosylation sites and enzymatic motifs on the AAV capsid surface to create variants that enter human liver cells more efficiently while showing lower sensitivity to neutralizing antibodies.18PubMed Central. Rational engineering of adeno-associated virus capsid enhances human hepatocyte tropism and reduces immunogenicity Other groups are pairing engineered capsids with tissue-specific promoters, internal genetic switches that ensure the delivered gene is only expressed in the intended tissue, which further reduces off-target immune reactions.19PubMed Central. Immunogenicity of Recombinant Adeno-Associated Virus Vectors for Gene Transfer
Much of this capsid-engineering work is happening in the context of gene therapy rather than vaccines, because conditions like hemophilia and inherited retinal diseases need the vector to deliver a functional gene to a specific tissue for long-term expression. But the lessons flow directly back into vaccine design. A vector that evades pre-existing antibodies is equally useful whether you are trying to deliver a missing clotting factor gene to the liver or a spike protein gene to muscle cells. The machine-learning component is accelerating the pace of discovery substantially, allowing researchers to screen vast libraries of capsid mutations computationally before synthesizing and testing the most promising candidates in the lab. The field is moving toward bespoke vectors designed for specific diseases, target tissues, and patient populations rather than the one-size-fits-all approach of the first-generation platforms.